Anti-ERBB3/ Erbb-3/ ErbB-3 monoclonal antibody

Anti-ERBB3/ Erbb-3/ ErbB-3 antibody for FACS & in-vivo assay

Target products collectionGo to Erbb-3/ERBB3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T86350-Ab-1/ GM-Tg-hg-T86350-Ab-2Anti-Human Erbb-3/ERBB3 monoclonal antibodyHuman
GM-Tg-rg-T86350-Ab-1/ GM-Tg-rg-T86350-Ab-2Anti-Rat Erbb-3/ERBB3 monoclonal antibodyRat
GM-Tg-mg-T86350-Ab-1/ GM-Tg-mg-T86350-Ab-2Anti-Mouse Erbb-3/ERBB3 monoclonal antibodyMouse
GM-Tg-cynog-T86350-Ab-1/ GM-Tg-cynog-T86350-Ab-2Anti-Cynomolgus/ Rhesus macaque Erbb-3/ERBB3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T86350-Ab-1/ GM-Tg-felg-T86350-Ab-2Anti-Feline Erbb-3/ERBB3 monoclonal antibodyFeline
GM-Tg-cang-T86350-Ab-1/ GM-Tg-cang-T86350-Ab-2Anti-Canine Erbb-3/ERBB3 monoclonal antibodyCanine
GM-Tg-bovg-T86350-Ab-1/ GM-Tg-bovg-T86350-Ab-2Anti-Bovine Erbb-3/ERBB3 monoclonal antibodyBovine
GM-Tg-equg-T86350-Ab-1/ GM-Tg-equg-T86350-Ab-2Anti-Equine Erbb-3/ERBB3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T86350-Ab-1/ GM-Tg-hg-T86350-Ab-2; GM-Tg-rg-T86350-Ab-1/ GM-Tg-rg-T86350-Ab-2;
GM-Tg-mg-T86350-Ab-1/ GM-Tg-mg-T86350-Ab-2; GM-Tg-cynog-T86350-Ab-1/ GM-Tg-cynog-T86350-Ab-2;
GM-Tg-felg-T86350-Ab-1/ GM-Tg-felg-T86350-Ab-2; GM-Tg-cang-T86350-Ab-1/ GM-Tg-cang-T86350-Ab-2;
GM-Tg-bovg-T86350-Ab-1/ GM-Tg-bovg-T86350-Ab-2; GM-Tg-equg-T86350-Ab-1/ GM-Tg-equg-T86350-Ab-2
Products NameAnti-Erbb-3/ERBB3 monoclonal antibody
Formatmab
Target NameErbb-3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-Erbb-3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-946Pre-Made Patritumab Deruxtecan Biosimilar, Whole Mab Adc, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-282Pre-Made Istiratumab biosimilar, Bispecific Mixed mAb and scFv, Anti-IGF1R;ERBB3/Erbb-3 Antibody: Anti-IGFR/CD221/IGFIR/JTK13;FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-c-erbB3/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
    BiosimilarGMP-Bios-ab-431Pre-Made Patritumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
    BiosimilarGMP-Bios-ab-048Pre-Made Barecetamab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
    BiosimilarGMP-Bios-ab-514Pre-Made Seribantumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
    BiosimilarGMP-Bios-ab-645Pre-Made Zenocutuzumab biosimilar, Bispecific mAb, Anti-ERBB3/Erbb-3;ERBB2/HER2 Antibody: Anti-FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
    BiosimilarGMP-Bios-ab-328Pre-Made Lumretuzumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
    BiosimilarGMP-Bios-ab-170Pre-Made Elgemtumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
    BiosimilarGMP-Bios-ab-157Pre-Made Duligotuzumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species ERBB3/ Erbb-3/ ErbB-3 VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T86350-Ag-1erb-b2 receptor tyrosine kinase 3 (ERBB3) protein
    ORF Viral VectorpGMAP000169Human ERBB3 Adenovirus plasmid
    ORF Viral VectorvGMAP000169Human ERBB3 Adenovirus particle


    Target information

    Target IDGM-T86350
    Target NameErbb-3
    Gene ID2065,13867,29496,711407,481105,101085388,785655,100059216
    Gene Symbol and Synonymsc-erbB-3,c-erbB3,ErbB-3,ERBB3,erbB3-S,Erbb3r,FERLK,HER3,LCCS2,MDA-BF-1,nuc-ErbB3,p180-ErbB3,p45-sErbB3,p85-sErbB3,VSCN1
    Uniprot AccessionP21860,Q62799
    Uniprot Entry NameERBB3_HUMAN,ERBB3_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseNon-Small Cell Lung Cancer, Prostate Cancer
    Gene EnsemblENSG00000065361
    Target ClassificationCheckpoint-Immuno Oncology, Kinase

    The target: Erbb-3, gene name: ERBB3, also named as ErbB-3, HER3, LCCS2, MDA-BF-1, c-erbB-3, c-erbB3, erbB3-S, p180-ErbB3, p45-sErbB3, p85-sErbB3. This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.